Nerviano Medical Sciences S.r.l. (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today that it has expanded its presence in the US with the creation of a new US subsidiary, Nerviano Medical Sciences Inc.
Nerviano Medical Sciences Inc. is incorporated in Delaware State while the company’s activities will be mostly concentrated in the Boston, Massachusetts area. The US subsidiary is part of NMS Srl and its holding NMS Group’s aggressive transformation plan to fortify further the Group’s footprint and accelerate its pace in expanding in the world’s key biotech and pharmaceutical market.
“NMS Srl has developed a unique and proprietary platform of First-in-Class and Best-in-Class assets where we are currently working either with multiple partners or by autonomously to advance our assets aggressively to registration. Since an important part of our revenue already comes from our US partners, having our physical presence in the US demonstrates yet again our commitment to strengthen our relationship with pharma, biotech and academics centers and to potentially expand further our pipeline” said Hugues Dolgos, PharmD chief executive officer of NMS Group and NMS Srl. “I’m delighted to open our first office in Boston as a proud resident in this biotech core of the country, said Lisa Mahnke, M.D., PhD, Chief Medical Officer of NMS Srl and Managing director of Nerviano Medical Sciences Inc. “We will start recruiting immediately key US-based roles to support the group, managing key R&D and commercial activities directly from our office. We expect to increase heavily our clinical programs through local partners to accelerate our speed with our oncology forward approach and deliver treatments to patients where there is an unmet need,” Lisa concluded.
20220801-NMS US Subsidiary-final